Biogen (BIIB) Change in Accured Expenses (2009 - 2026)

Biogen's Change in Accured Expenses history runs 18 years deep, the most recent figure standing at -$49.7 million for Q2 2026.

• In Q2 2026, Change in Accured Expenses fell 173.08% year-over-year to -$49.7 million; the TTM figure through Jun 2026 stood at -$222.2 million (up 41.8% YoY), while the FY2025 annual figure was -$248.0 million, down 38.78% from the prior year.
• Change in Accured Expenses for Q2 2026 stood at -$49.7 million, up from -$243.2 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $1.1 billion in Q2 2022, with the low at -$745.7 million in Q4 2022.
• The 5-year median for Change in Accured Expenses is -$72.1 million (2024), against an average of -$57.5 million.
• The sharpest annual moves came in 2022 and 2023: Change in Accured Expenses tumbled 854.76% in 2022, then soared 24864.71% in 2023.
• Biogen's Change in Accured Expenses stood at -$745.7 million in 2022, then soared by 33.55% to -$495.5 million in 2023, then jumped by 80.93% to -$94.5 million in 2024, then plunged by 127.83% to -$215.3 million in 2025, then surged by 76.92% to -$49.7 million in 2026.
• Business Quant data shows BIIB's Change in Accured Expenses at -$49.7 million in Q2 2026, -$243.2 million in Q1 2026, and -$215.3 million in Q4 2025.